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Introduction Multimorbidity, polypharmacy and susceptibility to adverse 
drug reactions (ADR) are common problems in old age.  Understanding the 
age-related biological changes that occur at a cellular level, may 
assist in identifying novel therapeutic targets.  The nuclear factor 
erythroid 2-like 2 (Nrf2) transcription factor regulates antioxidant 
and drug metabolising pathways in the cell.  Data from rodent models 
showed that Nrf2 protein expression declines with age.  If similar 
findings are observed in humans, it may help to explain why older 
people are vulnerable to multimorbidity and ADRs. This study 
investigates whether Nrf2 expression (both mRNA and protein) decreases 
with increasing age in humans. 
Methods  Fifty-five adults were recruited to our study (age range: 18-
75 years).  Participants donated 6 mL of venous blood, from which 
peripheral blood mononuclear cells (PBMCs) were separated and analysed 
for Nrf2 mRNA and protein expression (real time quantitative polymerase 
chain reaction and enzyme-linked immunosorbant assay respectively).    
Results Our data showed that Nrf2 protein expression was approximately 
50% lower in individuals aged >30 years (0.065 ±0.014 EU <30 years vs. 
0.033 ±0.0060 EU >30 years, p<0.05).  Similarly, mRNA expression 
declined with advancing age  (log2-fold change compared to 18-29 year-
olds: 1.08±1.19, 2.14±1.25, -0.69±1.15, 0.45±2.03, -4.76±2.06, in 30-
39, 40-49, 50-59, 60-69, >70 year age categories respectively; 
p<0.0001). 
Conclusions The expression of Nrf2 transcription factor is reduced in 
old age, potentially contributing to the increased risk of 
multimorbidity and adverse drug reactions. 
 
 
 
 
 
